Scientific article
OA Policy
English

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Published in

Open forum infectious diseases, vol. 10, no. 4, ofad150

Publication date

2023-04

First online date

2023-03-30

Abstract

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).

Keywords

  • HIV
  • Organ transplant
  • SARS-CoV-2
  • Vaccine
  • Randomized trial

Citation (ISO format)

GRIESSBACH, Alexandra et al. Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2). In: Open forum infectious diseases, 2023, vol. 10, n° 4, p. ofad150. doi: 10.1093/ofid/ofad150

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

2328-8957
156views
157downloads

Technical informations

Creation

24/09/2024 10:29:23

First validation

09/10/2024 15:06:33

Update

10/02/2026 08:04:22

Status update

10/02/2026 08:04:22

Last indexation

10/11/2026 18:05:01
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated